Provided herein are nanoparticle compositions (e.g., nanoparticle compositions comprising high atomic number ions) that are useful for imaging diseases in a subject as well as radiosensitizing a disease in a subject (e.g., radiosensitizing a cancer in the subject). Methods of imaging a subject, methods of treating cancer, and processes of preparing the nanoparticle compositions are also provided.

Provided are methods of treating a brain tumor in a patient in need thereof comprising administering to the patient a compound described herein and radiation therapy and/or one or more additional therapeutic agents.

The invention addresses radioresistance in cancer treatment involving radiotherapy and, in particular, limitations associated with the use of the drug sulfasalazine. Specifically, it provides a series of compounds for use as radiosensitizers in the treatment of cancers such as glioblastomas which are lethal and inherently resistant to radiotherapy. In one embodiment, the invention provides compounds of general formula (I), their stereoisomers and pharmaceutically acceptable salts for use as radiosensitizers in the treatment of cancer:

##STR00001##

wherein ring A is selected from optionally substituted phenyl, biphenyl and fluorenyl; each X is independently selected from: —C.sub.1-6 alkyl (preferably C.sub.1-3 alkyl, e.g. —CH.sub.3), —O—C.sub.1-6 alkyl (preferably —O—C.sub.1-3 alkyl, e.g. —OCH.sub.3), —S—C.sub.1-6 alkyl (preferably —S—C.sub.1-3 alkyl, e.g. —SCH.sub.3), —OH, —SH, —CO.sub.2R.sup.1 (where R.sup.1 is H or C.sub.1-6 alkyl, preferably C.sub.1-3 alkyl, e.g. —CH.sub.3), —SO.sub.2—C.sub.1-6 alkyl (preferably —SO.sub.2—C.sub.1-3 alkyl, e.g. —SO.sub.2—CH.sub.3), —SO.sub.2—NR.sup.2R.sup.3 (where R.sup.2 is H and R.sup.3 is optionally substituted phenyl), —NR.sup.4R.sup.5 (wherein R.sup.4 and R.sup.5 are independently selected from H, C.sub.1-6 alkyl (preferably C.sub.1-3 alkyl, e.g. —CH.sub.3), and —CO—C.sub.1-6 alkyl (preferably —CO—C.sub.1-3 alkyl, e.g. —CO—CH.sub.3), halogen (e.g. F, Cl or Br), and optionally substituted tetrazolyl; n is an integer from 0 to 5, preferably 0 to 2, e.g. 1 or 2; and denotes an E or Z double bond.

The invention relates to novel biocompatible hybrid nanoparticles of very small size, useful in particular for diagnostics and/or therapy. The purpose of the invention is to offer novel nanoparticles which are useful in particular as contrast agents in imaging (e.g. MRI) and/or in other diagnostic techniques and/or as therapeutic agents, which give better performance than the known nanoparticles of the same type and which combine both a small size (for example less than 20 nm) and a high loading with metals (e.g. rare earths), in particular so as to have, in imaging (e.g. MRI), strong intensification and a correct response (increased relaxivity) at high frequencies. Thus, the nanoparticles according to the invention, with diameter d.sub.1 between 1 and 20 nm, each comprise a polyorganosiloxane (POS) matrix including gadolinium cations optionally associated with doping cations; a chelating graft C.sup.1 DTPABA (diethylenetriaminepentaacetic acid bisanhydride) bound to the POS matrix by an —Si—C— covalent bond, and present in sufficient quantity to be able to complex all the gadolinium cations; and optionally another functionalizing graft Gf* bound to the POS matrix by an —Si—C— covalent bond (where Gf* can be derived from a hydrophilic compound (PEG); from a compound having an active ingredient PA1; from a targeting compound; from a luminescent compound (fluorescein). The method for the production of these nanoparticles and the applications thereof in imaging and in therapy also form part of the invention.

Disclosed herein are multifunctional nanoparticle compositions. The compositions can be useful for the treatment of cancer by enhancing the anti-tumor effectiveness of radiation directed to a tissue, cell or a tumor and the methods of use thereof. The multifunctional nanoparticle composition comprises a metal oxide nanoparticle core; a functional coating on the surface of the metal oxide nanoparticle core; and a matrix carrier in which the coated nanoparticle is embedded.

The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with Antibody Drug Conjugates (ADCs) ADCs which bind to CD25 (CD25-ADCs) and radiotherapy.

Nanoparticles comprising micheliolide (MCL) or derivatives thereof, and optionally additional therapeutic agents, such as chemotherapeutic agents, are described. Also described are methods of treating diseases, such as cancer, comprising the use of combinations of MCL or a derivative thereof with X-ray irradiation and/or other therapeutic agents, such as immune checkpoint inhibitors. The use of the combinations can provide synergistic anticancer therapeutic efficacy, for example, as the MCL or derivative thereof can both sensitize cancer cells to therapy and target resistant cancer stem cells (CSCs) for selective cell death.

The present invention concerns amphiphilic copolymers that may be photo- or redox-cleavable and that may assemble into polymersomes. It also concerns their process of preparation and their use as ding carriers.

The present invention provides: nanoparticles including a compound that includes porous silica and at least one high-atom selected from the group consisting of gadolinium atoms, iodine atoms, gold atoms, silver atoms, and platinum atoms; and a pharmaceutical composition for radiation treatment, useful for treatment of solid tumors, etc., and including these nanoparticles and a pharmaceutically acceptable carrier.

Devices, materials, compounds, systems, and processes for Cherenkov-Activated Nuclear-Targeted Photodynamic Therapy that involves generating Cherenkov light within the tissue of a target volume and using this light to activate photosensitizing material that is located in the nucleus of cells of the target volume.